Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RFID meeting

This article was originally published in The Tan Sheet

Executive Summary

A public workshop Feb. 8-9 will allow FDA's Counterfeit Drug Task Force to collect stakeholder input on identifying "incentives for widespread adoption of radio frequency identification (RFID), as well as obstacles," according to a Federal Register announcement Jan. 11. Specifically, the agency seeks input on how to address the likelihood that widespread RFID technology will not be in operation by the current deadline for implementation under the Prescription Drug Marketing Act's pedigree requirements. Comments will "guide the agency's decision whether to continue the delayed effective date, let the regulatory provisions go into effect, or take other steps," the announcement states. In 2004, FDA cited implementation of electronic track and trace capability by 2007 as a priority. However, "it appears that the goals described previously may not be met," FDA states...

Related Content

No Disguising Need For Enforcement, Education To Curb Counterfeiting





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts